Improving Memory in Patients With Multiple Sclerosis

United States Department of Health and Human Services (HHS)

Status and phase

Withdrawn

Phase 3

Conditions

Multiple Sclerosis

Treatments

Drug: glucose

Drug: donepezil

Study type

Interventional

Funder types

Other U.S. Federal agency

NIH

Identifiers

NCT00062972

1R01HD038107-01

Details and patient eligibility

About

People with multiple sclerosis (MS) suffer from cognitive and other brain problems. This study will examine the effectiveness of the drug donepezil and of sugar water for enhancing memory in individuals with MS. Donepezil (also known as Aricept) has been FDA approved for improving memory and learning in individuals with Alzheimer's disease.

Full description

Cognitive dysfunction is one of the leading causes of disability in people with MS. Memory involving specific words (verbal memory) is particularly affected in individuals with MS. Attempts to rehabilitate cognitive dysfunction in MS have had only limited success.

This study will determine the efficacy of donepezil therapy and glucose administration for enhancing verbal memory functioning in individuals with MS. The study will also measure secondary outcomes assessing other areas of cognitive dysfunction (i.e., nonverbal memory, conceptual thinking, processing speed) which may improve with intervention.

Forty participants with MS will be randomly assigned to receive either donepezil or placebo for 24 weeks. Participants will complete memory and cognitive tests at the beginning and end of the 24 week period.

Twenty participants with MS will be randomly assigned to drink a beverage sweetened with either glucose or saccharin (placebo). Participants will then complete memory and other cognitive tests. Two weeks later, participants will drink a beverage sweetened with the alternative sweetener and again complete the memory and cognitive tests.

Sex

All

Ages

18 to 56 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

MS as defined by the Poser criteria
Expanded Disability Status Scale (EDSS) score of 0 to 6.5
Stable neurologic function for at least 30 days prior to study entry
Agree to continue all current medications for study duration
Rey Auditory Verbal Learning Test score in low normal range or below
Mini-mental status exam score of 26 or higher
Montgomery-Asberg Depression Scale scaled score of 14 or lower
Fluent in English

Exclusion Criteria

Use of anticholinergic or benzodiazepine medication
Change in dosage of medications judged to have the potential to impact cognitive function (e.g., antispasticity medications) within 2 weeks of study entry
Current alcohol or substance abuse
History of neurological or major medical problem that has a known effect on cognitive functioning
History of noncompliance
Visual or upper extremity impairment which precludes ability to participate in cognitive assessment